Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iR2 in untreated and unfit elderly patients with DLBCL
NCT03949062Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Mar 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, lenalidomide, rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
ibrutiniblenalidomiderituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03949062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03949062.